Imugene Limited (IMU.AX) Stock Analysis

Imugene CEO on Phase 1b azer-cel data: second complete response

Wed, July 1, 2026 at 7:15 AM UTC 4 min read

Imugene (IMU.AX) announced that its CEO highlighted a second complete response in the Phase 1b clinical trial for azer-cel, a promising cancer treatment. This development is significant for investors as it demonstrates the potential efficacy of the therapy, potentially paving the way for further advancements and increased investor confidence in Imugene's pipeline. Positive trial results could enhance the company's market position and attract interest from potential partners or acquirers.

Read full article →

Imugene reports second complete response in azer-cel BTKi cohort

Wed, July 1, 2026 at 12:59 AM UTC 4 min read

Imugene (IMU.AX) announced a second complete response in its azer-cel BTKi cohort, indicating promising efficacy in its ongoing clinical trials. This development is significant for investors as it highlights the potential of Imugene's therapies in treating specific cancers, potentially enhancing the company's market position and attracting further investment. Continued positive results could lead to increased confidence in the company's pipeline and future revenue opportunities.

Read full article →